Anti-Obesity Drugs Market Overview Analysis By Fortune Business Insights
Market Summary
According to Fortune Business Insights: The global anti-obesity drugs market was valued at USD 7.48 billion in 2025 and is projected to grow from USD 8.65 billion in 2026 to USD 67.16 billion by 2034, at a CAGR of 29.20% during the forecast period. Anti-obesity drugs are pharmacological agents prescribed or available over the counter to manage chronic weight conditions in adults with obesity or overweight with at least one weight-related comorbidity. These drugs work through mechanisms including appetite suppression, reduced fat absorption, and GLP-1 receptor agonism, targeting the severe health consequences of obesity — including insulin resistance, glucose intolerance, hypertension, sleep apnea, diabetes mellitus, arthritis, gallbladder diseases, and certain cancers. North America dominated the market with a 65.82% share in 2025, valued at USD 4.93 billion.
Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/104783
Key Market Drivers
The escalating global prevalence of obesity is the primary market driver. The World Obesity Federation's World Obesity Atlas 2023 projected that 4.0 billion people globally will live with obesity by 2035 if current trends continue, with the economic impact expected to surpass USD 4.32 trillion annually. In the United States, obesity-associated cancers now exceed 684,000 cases per year according to CDC estimates, with breast and colorectal cancers being the most common among women and men respectively. The significant rise in obesity prevalence has created a large patient population suffering from chronic, debilitating comorbidities that severely affect daily functioning and mortality — directly expanding demand for effective pharmacological weight management.
A robust and expanding pipeline of anti-obesity drugs by market players is a defining market trend. As the scale of obesity as a public health challenge has become clearer, leading pharmaceutical companies are investing heavily in R&D for novel therapeutic approaches. In June 2023, Eli Lilly's retatrutide — an investigational GLP-1/GIP/glucagon tri-agonist — entered clinical evaluation for obesity and type 2 diabetes with once-weekly injection dosing. In May 2023, Innovent Biologics' Phase 2 clinical study of mazdutide (IBI362) at a 9 mg dose achieved positive outcomes in Chinese adults with obesity, reflecting the breadth of global pipeline activity. New product approvals and launches are expected to be the primary commercial growth catalyst throughout the forecast period.
Growing awareness regarding obesity treatment is reinforcing structural demand. International health organizations are actively expanding public understanding of obesity as a chronic, treatable disease. In March 2023, the World Obesity Federation launched its "Changing Perspectives: Let's Talk About Obesity" campaign on World Obesity Day, targeting misconceptions and encouraging access to pharmacological and clinical interventions. Combined with increasing endorsement of anti-obesity drugs by healthcare professionals and growing availability through telehealth platforms, awareness-building is accelerating early and preventive drug adoption.
Market Restraints and Challenges
Stringent drug approval policies are the primary market restraint. The regulatory process for new anti-obesity drug approval is demanding and time-consuming, deterring investment and limiting the pace of market entry. The European Medicines Agency has issued regulatory approvals for only three drug therapies — orlistat, bupropion/naltrexone, and liraglutide — compared to five approvals from the U.S. FDA. Most regulatory frameworks apply a threshold of at least 5% total weight loss to determine therapeutic significance, and meeting this standard consistently across clinical trial populations significantly increases development risk, time, and expense. These barriers raise R&D costs, limit pipeline-to-market conversion, and restrict revenue growth for companies seeking to enter or expand within the global market.
Segmentation Analysis
By type, the prescription drugs segment is expected to dominate the market with a 93.71% share in 2026. The dominance of prescription drugs reflects the clinical complexity of obesity management and the critical role of healthcare professional oversight in initiating and monitoring pharmacological treatment. Key players are driving adoption through R&D investment, strategic partnerships, and patient access initiatives. In January 2024, Eli Lilly launched LillyDirect, a dedicated website enabling patients to access the weight loss drug Zepbound through telehealth — significantly reducing barriers to prescription initiation. The OTC drugs segment is growing at a lower CAGR, constrained by limited product offerings and consumer concerns about adverse side effects without professional guidance.
By distribution channel, the retail and online pharmacy segment is projected to dominate with a 96.32% share in 2026. The predominance of retail and online pharmacies reflects the chronic nature of obesity treatment — requiring long-term drug adherence and regular prescription refills — and the growing availability of anti-obesity drugs through e-pharmacy platforms that offer cost efficiency, convenience, and continuity of supply. The hospital pharmacy segment is growing at a lower CAGR, as patients increasingly shift to out-of-hospital procurement channels for ongoing weight management medications.
Regional Outlook
North America leads the global market at USD 4.93 billion in 2025, projected at USD 5.64 billion in 2026, driven by the high prevalence of obesity, elevated healthcare expenditure per person, and the highest adoption rates for novel anti-obesity therapies. According to the National Library of Medicine, annual medical care costs for adults with obesity in the U.S. reach USD 2,505 per person and increase significantly with obesity class — from 68.4% for Class 1 to 233.6% for Class 3. The U.S. market alone is projected at USD 5.11 billion in 2026. Europe is the second-largest region at USD 1.20 billion in 2025, projected at USD 1.42 billion in 2026, anchored by the presence of Novo Nordisk and strong R&D investment; Germany is projected at USD 0.34 billion and the U.K. at USD 0.29 billion in 2026. According to the United Nations, obesity costs in all age groups are projected to reach USD 800 billion for the WHO European region by 2035. Asia Pacific contributed USD 0.83 billion in 2025 (11.13% global share), projected at USD 1.00 billion in 2026, with rising obesity prevalence across the region — nine of the ten countries with the greatest increase in obesity globally are from Asia and Africa according to the World Obesity Atlas 2023. China is projected at USD 0.27 billion, Japan at USD 0.19 billion, and India at USD 0.11 billion in 2026. Latin America and the Middle East and Africa represent smaller market shares at USD 0.21 billion and USD 0.31 billion respectively in 2025, constrained by lower healthcare expenditure per person and more limited awareness and infrastructure for obesity pharmacotherapy.
Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/104783
Competitive Landscape
The global anti-obesity drugs market is consolidated, with a few players commanding dominant positions through regulatory approvals, pipeline depth, and commercial scale. Novo Nordisk A/S holds the leading market position, anchored by Wegovy (semaglutide) — approved by the U.S. FDA in June 2021 for chronic weight management — and growing international regulatory approvals. The CHMP adopted a positive opinion recommending Wegovy's EU marketing authorization in November 2021. Other key players include Eli Lilly and Company (U.S.), GlaxoSmithKline plc (U.K.), VIVUS LLC. (U.S.), Currax Pharmaceuticals LLC (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sandoz International GmbH — Novartis AG (Germany), and Boehringer Ingelheim International GmbH (Germany). In November 2023, Eli Lilly received FDA approval for Zepbound (tirzepatide) for chronic weight management in adults with obesity. In February 2022, Pfizer's GLP-1 receptor program demonstrated potential to contribute to weight loss alongside type 2 diabetes control. In April 2021, Zealand Pharma and Boehringer Ingelheim initiated Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for overweight or obese adults.
What Everyone Should Know About Japan’s Market - Anti-obesity Drugs Market Insights